Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's (NYSE:LLY) recent earnings report. Eli Lilly reported a significant miss in GLP-1 revenue, attributing it to stock shortages and increased competition from compounders. This development has raised concerns about the sustainability of compounded GLP-1 medications, which are a part of Hims' product offerings.
Earnings Preview for Hims
Looking ahead to its upcoming earnings report, Hims is expected to present its results next week, with analysts watching closely for signs of demand resilience across its telehealth and wellness offerings. The Street projects revenue of approximately $382 million for the quarter, which represents a 69% growth year-over-year, reflecting solid growth as Hims continues to expand its customer base and offerings. Management has guided for adjusted EBITDA with a midpoint of $38 million, and analysts anticipate a slight profit of around $0.04 per share, an improvement over the same period last year, which reported a loss of $0.04 per share, as the company edges closer to profitability.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。